A5058031556- Prostate Cancer Treatment and Research
- Radiomics and Machine Learning in Medical Imaging
- Prostate Cancer Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Protease and Inhibitor Mechanisms
- Thyroid Cancer Diagnosis and Treatment
- Molecular Biology Techniques and Applications
- Urologic and reproductive health conditions
- Advanced Proteomics Techniques and Applications
- Glycosylation and Glycoproteins Research
- Connective Tissue Growth Factor Research
- Cancer, Lipids, and Metabolism
- Blood Coagulation and Thrombosis Mechanisms
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
University of Helsinki
2021-2024
Helsinki University Hospital
2021-2023
Abstract Magnetic resonance imaging (MRI) is increasingly used to triage patients for prostate biopsy. However, 9% 24% of clinically significant (cs) cancers (PCas) are not visible in MRI. We aimed identify histomic and transcriptomic determinants MRI visibility their association metastasis, PCa‐specific death (PCSD). studied 45 radical prostatectomy‐treated with csPCa (grade group [GG]2‐3), including 30 MRI‐visible 15 MRI‐invisible lesions, 18 men without PCa. First, histological...
The use of MRI-targeted biopsies has led to lower detection Gleason Grade Group 1 (GG1) prostate cancer and increased GG2 disease. Although this finding is generally attributed improved sensitivity specificity MRI for aggressive cancers, it might also be explained by grade inflation. Our objective was determine the likelihood definitive treatment risk post-treatment recurrence patients with diagnosed using targeted relative men GG1 systematic biopsies.
Abstract We aimed to study mRNA levels and prognostic impact of all 15 human kallikrein‐related peptidases ( KLK s) their targets, proteinase‐activated receptors PAR s), in surgically treated prostate cancer (PCa). Seventy‐nine patients with localized grade group 2‐4 PCas represented aggressive cases, based on metastatic progression during median follow‐up 11 years. Eighty‐six similar baseline characteristics, but no metastasis follow‐up, were assigned as controls. Transcript counts detected...
Abstract Background Improved prognostication is needed to minimize overtreatment in grade group (GG) 2–4 prostate cancer. Our aim was determine, at messenger RNA (mRNA) level, the performance of genes commercial panels Decipher, Oncotype DX, Prolaris, and mutational panel MSK‐IMPACT predict metastasis‐free cancer‐specific death (PCSD) patients with GG cancer radical prostatectomy. Methods The retrospective cohort consisted treated prostatectomy (median follow‐up 10.4 years). Seventy‐six...
Abstract CUB domain-containing protein 1 (CDCP1) is a type transmembrane overexpressed in many cancers, including prostate cancer. CDCP1 has been associated with tumor progression, metastasis, drug resistance and poor prognosis cancer, making it potential prognostic biomarker therapeutic target. It shown to be subset of castration resistant cancers (CRPC) cooperate the loss suppressor PTEN promote metastatic dissemination. Extracellular serine proteases activate by cleaving into an...
Abstract Introduction Prostate cancer (PCa) ranks as the second most frequently diagnosed in male population worldwide. The challenge effectively managing PCa is absence of well-established biological markers, which often leads to both over and under treatment. To address this issue, a deeper understanding molecular alterations within essential for more accurate patient stratification. In research, we embark on comprehensive examination how presence fibroblast activation protein (FAP) alpha...
Abstract Introduction: Multiplexed fluorescence immunohistochemistry (mfIHC) allows the detection of multiple protein markers on same histological tissue section, generating valuable information specific cell subsets and cellular states in their spatial context. Here, we demonstrate a proof-of-concept study for profiling different tumor microenvironment formalin-fixed paraffin-embedded prostate cancer microarrays. Materials methods: We applied automated mfIHC simultaneous staining 31 slides...
Abstract Changes in protein glycosylation have been observed several cancers, where they affect cellular growth behavior, invasiveness and acquisition of metastatic potential. Such changes are not random found to associate with cancer aggressiveness. Thus, detection may offer novel opportunities for biomarker development. Since prostate-specific antigen (PSA) is glycosylated, assessing different PSA-glycoforms provide valuable diagnostic prognostic information. We recently established a situ...
Abstract SerpinE2, also known as protease nexin-1, is an extracellular serine inhibitor modulating the activity of proteases such thrombin, plasmin, urokinase-type plasminogen activator and trypsin. Dysregulation between their cognate inhibitors has been implicated in malignant progression, making serpins promising biomarkers for tumor progression prognosis. SerpinE2 upregulated many cancers promotes invasion metastasis. In this study, we analyzed serpinE2 expression by immunohistochemistry...
Abstract Prostate cancer (PCa) diagnostics are shifting towards multi-parametric magnetic resonance imaging (MRI) combined with targeted biopsies. However, some 10% of clinically significant PCa (csPCa) is missed current MRI sequences. Evidence on biological differences between visible and invisible csPCa scarce. Our aim was to find out, whether lesions harbor more indolent characteristics compared lesions, identify transcript markers visibility. Methods: A retrospective cohort 45 radical...